外源性锌金属硫蛋白对肿瘤患者放化疗的临床研究

Impact of exogenous zinc metallothionein for the oncology patients who received chemotherapy or radiotherapy

目的观察金属硫蛋白制剂对肿瘤患者放化疗的疗效及不良反应。方法将符合入组条件的113例患者随机分为观察组(57例)和对照组(56例),观察组在常规放化疗前3天开始口服外源性锌金属硫蛋白制剂,每天1.8mg,配合常规放疗和(或)化疗直至治疗结束;对照组常规放疗和(或)化疗。两组患者在治疗前、治疗中和治疗后分别测定血常规、肝肾功能、心肌酶、CD3+和CD4+T淋巴细胞等以及治疗结束1个月后的缓解率(CR+PR)和3年生存率。结果两组患者的CD3+和CD4+T淋巴细胞在放化疗过程中呈下降趋势,但观察组治疗后的CD3+和CD4+T淋巴细胞高于对照组,差异有统计学意义(P﹤0.05);两组患者的外周血白细胞计数、血红蛋白量、血小板计数、心肌酶(CK)、肝功能(ALT和AST)、肾功能(BUN和Scr)在治疗前、治疗中及治疗后比较,差异无统计学意义(P>0.05);两组患者治疗后的客观缓解率和3年生存率比较,差异无统计学意义(P>0.05)。结论外源性锌金属硫蛋白对放化疗引起的T细胞损伤有保护作用,而对血常规、肝肾功能、心肌酶、放化疗的疗效及治疗后的3年生存率无明显影响。

Objective Research the impact of metallothionein to oncology patients whom received chemotherapy or radiotherapy.Methods The oncology patients were randomly divided into two groups,observation group contained 57 patients and control group contained 56 patients.Chemotherapy or radiotherapy began 3 days ago,observation patients took the exogenous zinc-metallothionein 1.8mg a day until the end of therapy while control patients just received chemotherapy or radiotherapy.We examined blood tests,liver functions,kidney functions,CD ＋ 3 T lymphocytes,CD ＋ 4 T lymphocytes,myocardial enzymes of the two groups before the treatment, treatment and after treatment,and recorded remission rate,3 years survival rate after treatment.Results After chemotherapy or radiotherapy,the CD ＋ 3 T lymphocytes and CD ＋ 4 T lymphocytes of two groups reduced all,but the control group was lower than observation group.In the test,the blood tests,myocardial enzymes,liver and kidney functions,remission rate,3 years survival rate of two groups were no differences.Conclusions The exogenous zinc metallothionein could prevent CD ＋ 3 T lymphocytes and CD ＋ 4 T lymphocytes from damaging of chemotherapy or radiotherapy,but had little influence on blood tests,liver and kidney functions,myocardial enzymes,remission rate,3 years survival rate of chemotherapy or radiotherapy.